On Friday, Keryx Biopharmaceuticals (NASDAQ:KERX)’s shares declined -3.1% to $10.33.
Keryx Biopharmaceuticals (KERX) declared its financial results for the first quarter ended March 31, 2015.
First Quarter 2015 Business Highlights
- For the quarter ended March 31, 2015, Keryx stated total revenue of about $1.2 million, counting net U.S. Auryxia product revenue and license revenue associated with royalties received on sales of Riona(R) (ferric citrate) in Japan. The Company recognized U.S. product sales based on 1,218 prescriptions filled for Auryxia during the quarter, based on data received from IMS Health and specialty pharmacies that don’t report data to IMS, counting Davita Rx and Fresenius Rx.
- In January 2015, Keryx accomplished an underwritten public offering of common stock, which offered proceeds to the Company of about $118.3 million, net of underwriting discounts and offering expenses. Keryx ended the first quarter with $168.8 million in cash and cash equivalents. Additionally, the Company ended the first quarter with about $27.2 million of inventory on its merged balance sheet, primarily comprising of Auryxia active pharmaceutical ingredient.
Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on providing therapies for patients with renal disease in the United States. Its lead product Auryxia (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes, in addition to treats iron deficiency anemia.
ONEOK, Inc. (NYSE:OKE)’s shares dropped -2.06% to $44.15.
ONEOK, Inc. (OKE) held its first Annual Meeting of Shareholders recently, May 21, 2015, at company headquarters in Tulsa, Okla.
ONE Gas President and Chief Executive Officer, Pierce H. Norton II, talk abouted the accomplishments and highlights of 2014 – the company’s first year as an independent company. Norton also took time to thank the board of directors, the company’s 3,300 employees and its retirees.
The company declared and paid three dividends, and in January 2015, raised the dividend 7 percent.
Shareholders approved the following proposals:
- Election of three directors to the ONE Gas Board of Directors each for a three-year term;
- Selection of PricewaterhouseCoopers LLP as the company’s independent registered public accounting firm for 2015
ONEOK, Inc. engages in the gathering, processing, storage, and transportation of natural gas in the United States. It operates in Natural Gas Gathering and Processing, Natural Gas Liquids, and Natural Gas Pipelines segments.
At the end of Friday’s trade, Windstream Holdings, Inc. (NASDAQ:WIN)‘s shares dipped -2.93% to $8.27.
Windstream Holdings, Inc. (WIN) board of directors declared a prorated $.15 per share quarterly dividend to Windstream shareholders.
Shareholders of record on June 30, 2015, will receive a cash dividend of $.1104 per share, which represents a prorated dividend for the period April 25, 2015 through June 30, 2015. The dividend is payable on July 15, 2015.
Windstream Holdings, Inc. provides communications and technology solutions in the United States. It offers managed services and cloud computing services to businesses, in addition to broadband, voice, and video services to consumers primarily in rural markets.
Cytori Therapeutics Inc (NASDAQ:CYTX), ended its Friday’s trading session with -3.05% loss, and closed at $0.660.
Cytori Therapeutics Inc (CYTX) declared its first quarter financial results and offered updates on its corporate activity and clinical development.
Selected Q1 Highlights:
Cytori received FDA IDE full approval for Pivotal Phase III trial, STAR TRIAL, to evaluate ECCS-50 in treating hand dysfunction associated with scleroderma – Jan’ 2015
FDA approved an enhance in number of STAR trial sites from 12 to 20 – Feb’ 2015
Enrollment began for ACT-OA, a 90 patient, US Phase II trial, to study ECCO-50 in treating osteoarthritis of the knee - Feb’ 2015
Cytori and Lorem Vascular were granted regulatory clearance for Cytori Celution® System by the State Food and Drug Administration of the People’s Republic of China – Apr’ 2015
Cytori received initial purchase order of Celution devices and 1,100 consumable sets from Lorem Vascular, our Chinese Licensee – Apr’ 2015
Cytori was granted orphan drug status for treatment of scleroderma in European Union – Apr’ 2015
Cytori Therapeutics, Inc., a biotechnology company, develops cell therapeutics for specific diseases and medical conditions. The company primarily provides Cytori Cell Therapy comprising of a heterogeneous population of specialized cells, counting stem cells for the treatment of patients with scleroderma hand dysfunction, orthopedic disorders, cardiovascular disease, urinary incontinence, and thermal burns combined with radiation injury.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
